UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 35, 2026

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41463

46-5211056

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class	Trading Symbols	Name of each exchange on which registered
Common Stock, par value $0.007 per share	BIAF	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Warrants to purchase Common Stock	BIAFW	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 85.0102. ~~Other~~Departure ~~Events~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 35, 2026, Robert Anderson and Roby Joyce informed the Board of Directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), ~~issued~~of atheir ~~press~~decisions ~~release~~not ~~announcing that~~to itstand ~~presented~~for are-election ~~poster~~to ~~entitled~~the ~~“Sputum~~Board asupon aexpiration of ~~Diagnostic~~their ~~Tool~~current ~~for~~terms, ~~the~~which ~~Treatment~~expire ofat ~~Asthma” (~~the ~~“Poster”) at~~Company’s ~~the~~2026 ~~American~~Annual ~~Academy~~Meeting of ~~Allergy~~Stockholders, ~~Asthma~~currently ~~and~~scheduled ~~Immunology~~for ~~(AAAAI)~~April ~~2026 annual meeting in Philadelphia~~30, ~~PA,~~2026 (the on“Annual ~~March~~Meeting”). ~~1, 2026~~Mr. ~~The~~Anderson’s ~~Poster reports~~and onMr. ~~the Company~~Joyce’s ~~development~~decisions ofnot ~~clinical~~to ~~diagnostics~~stand ~~that~~for ~~may~~re-election ~~assist~~at ~~physicians~~the inAnnual ~~matching asthma and COPD patients with~~Meeting ~~effective~~did ~~therapies~~not ~~and~~result ~~how~~from ~~monitoring~~any ~~inflammatory~~disagreements ~~changes~~with ~~over~~the ~~time~~Company ~~can~~on ~~improve~~any ~~outcomes~~matter ~~and~~relating ~~lower~~to the ~~cost~~Company’s ofoperations, ~~healthcare~~policies or practices.

Copies of the press release and Poster are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated March 3, 2026
99.2		Poster entitled “Sputum as a Diagnostic Tool for the Treatment of Asthma”
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 3, 2026	BIOAFFINITY TECHNOLOGIES, INC.
Date: March 6, 2026	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

Filing Compare · bioAffinity Technologies, Inc.